A PhaseI/II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carustine, Etoposide, Cytarabine and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosi